ERBB2 and cancer: Similar to findings with other members of the ErbB family (EGFR/HER1, HER2, HER3), our study shows HER4 activation in NSCLC cancer cells can result in growth cell mediated by activation through GPCR transactivation or by direct ligand activation by ErbB member ligands through a ROS-mediated process.